2023
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile
Grajales V, Contieri R, Tan W, Flores M, Schultz M, Pinochet R, Bustamante A, Kamat A, Fernández M. Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile. Bladder Cancer 2023, 9: 327-334. PMID: 38994240, PMCID: PMC11165921, DOI: 10.3233/blc-230047.Peer-Reviewed Original ResearchNon-muscle invasive bladder cancerBacillus Calmette-GuerinBacillus Calmette-Guerin treatmentHR-NMIBC patientsInvasive bladder cancerOncological outcomesHigh riskBladder cancerHigh-risk non-muscle invasive bladder cancerPatients treated with bacillus Calmette-GuerinAdjuvant bacillus Calmette-GuerinBacillus Calmette-Guerin instillationsFull doseFD groupMultivariate Cox regression modelCalculate survival estimatesReduced-dose regimensMedian follow-upRecurrence free rateKaplan-Meier methodReduced toxicity profileCox regression modelsHR-NMIBCStratify patientsRetrospective studyOncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian follow-upInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removalInternational Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. International Bladder Cancer Group Intermediate-risk Nonmuscle-invasive Bladder Cancer Scoring System Predicts Outcomes of Patients on Active Surveillance. Journal Of Urology 2023, 210: 763-770. PMID: 37535836, DOI: 10.1097/ju.0000000000003639.Peer-Reviewed Original ResearchTransurethral resection of bladder tumorResection of bladder tumorNonmuscle-invasive bladder cancerTransurethral resectionBladder tumorsActive surveillanceBladder cancerScoring systemNonmuscle-invasive bladder cancer patientsAbsence of gross hematuriaMultivariate Cox proportional hazards analysisRisk factorsNonmuscle-invasive bladder tumorsNegative urinary cytologyCox proportional hazards analysisMedian follow-upMultivariate Cox regressionBladder cancer patientsProportional hazards analysisUrinary cytologyGross hematuriaT stageLandmark time pointsFollow-upCox regressionSequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer
Tan W, McElree I, Davaro F, Steinberg R, Bree K, Navai N, Dinney C, O'Donnell M, Li R, Kamat A, Packiam V. Sequential Intravesical Gemcitabine and Docetaxel is an Alternative to Bacillus Calmette-Guérin for the Treatment of Intermediate-risk Non–muscle-invasive Bladder Cancer. European Urology Oncology 2023, 6: 531-534. PMID: 37468392, DOI: 10.1016/j.euo.2023.06.011.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinIntermediate-risk non-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancerIntermediate-riskMulti-institutional retrospective reviewBlue light cystoscopyCombination of docetaxelEvaluate oncological outcomesHigh-grade diseaseMedian follow-upCancer-specific mortalityTreatment groupsCancer control outcomesBladder cancer groupSequential gemcitabineChemotherapy combinationsOncological outcomesIntravesical gemcitabinePostoperative chemotherapyAdjuvant treatmentRetrospective reviewRecurrence rateCancer groupBladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes
Tan W, Grajales V, Contieri R, Hensley P, Bree K, Msaouel P, Guo C, Nogueras-Gonzalez G, Navai N, Dinney C, Kamat A. Bladder-sparing Treatment in Patients with Bacillus Calmette-Guerin–unresponsive Non–muscle-invasive Bladder Cancer: An Analysis of Long-term Survival Outcomes. European Urology Open Science 2023, 53: 16-22. PMID: 37441349, PMCID: PMC10334230, DOI: 10.1016/j.euros.2023.04.013.Peer-Reviewed Original ResearchNon-muscle-invasive bladder cancerBladder-sparing treatmentLong-term survival outcomesCancer-specific survivalBCG-unresponsive NMIBC patientsEarly radical cystectomyRadical cystectomySurvival outcomesOverall survivalBladder cancerDelayed RCNMIBC patientsEarly RCAnalysis of long-term survival outcomesHigh-grade recurrenceProgression-free rateRecurrence-free rateMedian follow-upShort-term outcomesLong-term outcomesCurrent smoker statusCT1 diseaseLymphovascular invasionVariant histologyPrimary endpoint
2022
Comparison of Long-term Outcomes for Young and Healthy Patients with cT1a and cT3a Renal Cell Carcinoma Treated with Partial Nephrectomy
Tan W, Koelker M, Campain N, Cole A, Labban M, Mossanen M, Barod R, Kibel A, Chang S, Bex A, Trinh Q. Comparison of Long-term Outcomes for Young and Healthy Patients with cT1a and cT3a Renal Cell Carcinoma Treated with Partial Nephrectomy. European Urology Focus 2022, 9: 333-335. PMID: 36241545, DOI: 10.1016/j.euf.2022.09.018.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaLocally advanced kidney cancerPositive surgical marginsPartial nephrectomyAdvanced kidney cancerSurgical marginsKidney cancerRate of surgical marginComparison of long-term outcomesNational Cancer DatabaseMedian follow-upPatients aged <Cox proportional-hazards modelLong-term outcomesPresence of tumorCharlson Comorbidity IndexChronic kidney diseaseProportional-hazards modelCT1a tumorsCT1b groupHigher ACMNephron preservationCT stagingSolitary kidneyCell carcinoma
2019
Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis
Tan W, Trinh Q, Hayn M, Marchese M, Lipsitz S, Nabi J, Kilbridge K, Vale J, Khoubehi B, Kibel A, Sun M, Chang S, Sammon J. Delayed nephrectomy has comparable long-term overall survival to immediate nephrectomy for cT1a renal cell carcinoma: A population-based analysis. Urologic Oncology Seminars And Original Investigations 2019, 38: 74.e13-74.e20. PMID: 31864937, DOI: 10.1016/j.urolonc.2019.11.008.Peer-Reviewed Original ResearchConceptsRenal cell carcinomaCT1a renal cell carcinomaImmediate nephrectomyKaplan-Meier curvesOverall survivalCell carcinomaSurgical resectionRenal massesPatient ageTreatment armsCharlson Comorbidity Index 0Compare OS of patientsLong-term overall survivalInfluence of patient ageCox proportional hazards regression analysisEarly surgical resectionLong-term OSMedian patient ageProportional hazards regression analysisMedian follow-upNational Cancer DatabaseOS of patientsSmall renal massesInverse probabilityRecommended treatment optionOpen Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes
Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan W, Kelly J, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, Briganti A, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz P, Rouprêt M, Koupparis A, Kassouf W, Scherr D, Ploussard G, Boorjian S, Lotan Y, Sooriakumaran P, Shariat S. Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. Journal Of Clinical Medicine 2019, 8: 1192. PMID: 31395826, PMCID: PMC6722857, DOI: 10.3390/jcm8081192.Peer-Reviewed Original ResearchRobot-assisted radical cystectomyOpen radical cystectomyCancer-specific mortalitySurvival outcomesRadical cystectomyPropensity score matchingBladder cancerPatients treated with robot-assisted radical cystectomyAssociation of surgical techniqueLong-term survival outcomesCancer-specific mortality ratesMultivariate Cox regression analysisMultivariate competing risk analysisOpen radical cystectomy patientsRobot-assisted radical cystectomy patientsBilateral pelvic lymphadenectomyCompare survival outcomesMedian follow-upUrothelial bladder cancerScore matchingCox regression analysisPropensity-matched cohortCompeting risk analysisPelvic lymphadenectomyMulticentre cohortComparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals
Tan W, Berg S, Cole A, Krimphove M, Marchese M, Lipsitz S, Nabi J, Sammon J, Choueiri T, Kibel A, Sun M, Chang S, Trinh Q. Comparing Long-Term Outcomes Following Radical and Partial Nephrectomy for cT1 Renal Cell Carcinoma in Young and Healthy Individuals. JNCI Cancer Spectrum 2019, 3: pkz003. PMID: 31360891, PMCID: PMC6649692, DOI: 10.1093/jncics/pkz003.Peer-Reviewed Original ResearchLow-stage renal cell carcinomaRenal cell carcinomaTreated with radical nephrectomyInverse probability of treatment weighting adjustmentPartial nephrectomyRadical nephrectomyType of surgeryOverall survivalTreatment weighting adjustmentCell carcinomaClinical stageCompare overall survival of patientsPatients treated with partial nephrectomyLong-term overall survivalCT1 renal cell carcinomaOverall survival of patientsCox proportional hazards regression analysisProportional hazards regression analysisCompare overall survivalNational Cancer DatabaseMedian follow-upSurvival of patientsKaplan-Meier curvesInverse probabilityLong-term outcomes
2018
BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004)
Kelly J, Tan W, Porta N, Mostafid H, Huddart R, Protheroe A, Bogle R, Blazeby J, Palmer A, Cresswell J, Johnson M, Brough R, Madaan S, Andrews S, Cruickshank C, Burnett S, Maynard L, Hall E, Investigators O. BOXIT—A Randomised Phase III Placebo-controlled Trial Evaluating the Addition of Celecoxib to Standard Treatment of Transitional Cell Carcinoma of the Bladder (CRUK/07/004). European Urology 2018, 75: 593-601. PMID: 30279015, DOI: 10.1016/j.eururo.2018.09.020.Peer-Reviewed Original ResearchMeSH KeywordsAdministration, IntravesicalAgedAntibiotics, AntineoplasticAntineoplastic Combined Chemotherapy ProtocolsBCG VaccineCarcinoma, Transitional CellCardiovascular DiseasesCelecoxibCyclooxygenase 2 InhibitorsDisease ProgressionDouble-Blind MethodFemaleHumansMaleMiddle AgedMitomycinNeoplasm Recurrence, LocalNeoplasm StagingQuality of LifeRisk AssessmentRisk FactorsTime FactorsTreatment OutcomeUnited KingdomUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerHigh-risk non-muscle-invasive bladder cancerRisk of recurrenceIncreased risk of cardiovascular eventsRisk of cardiovascular eventsTime to recurrenceCardiovascular eventsNMIBC patientsBladder cancerStandard treatmentPhase III placebo-controlled trialIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancer patientsIncreased riskPatients treated with celecoxibWeekly mitomycin C instillationsMitomycin C instillationAdjuvant intravesical therapyRecurrence-free rateMedian follow-upPlacebo-controlled trialTransitional cell carcinomaHigh-risk patientsCyclo-oxygenase 2 inhibitorsIntravesical therapyRadiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial
Tan W, Panchal A, Buckley L, Devall A, Loubière L, Pope A, Feneley M, Cresswell J, Issa R, Mostafid H, Madaan S, Bhatt R, McGrath J, Sangar V, Griffiths T, Page T, Hodgson D, Datta S, Billingham L, Kelly J. Radiofrequency-induced Thermo-chemotherapy Effect Versus a Second Course of Bacillus Calmette-Guérin or Institutional Standard in Patients with Recurrence of Non–muscle-invasive Bladder Cancer Following Induction or Maintenance Bacillus Calmette-Guérin Therapy (HYMN): A Phase III, Open-label, Randomised Controlled Trial. European Urology 2018, 75: 63-71. PMID: 30274699, DOI: 10.1016/j.eururo.2018.09.005.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerDisease-free survival timeCarcinoma in situBacillus Calmette-GuerinSecond-line therapyTreatment armsComplete responseOpen-labelNo significant differenceBladder cancerCourse of bacillus Calmette-GuerinNon-muscle-invasive bladder cancer patientsBacillus Calmette-Guerin failuresCarcinoma in situ patientsStandard second-line therapyBacillus Calmette-Guerin therapyRecurrence of non-muscle-invasive bladder cancerStandard of care treatmentControlled trialsPapillary bladder lesionsPhase III randomised controlled trialMedian follow-upBladder cancer outcomesSignificant differenceOutcome measures
2016
Analysis of open and intracorporeal robotic assisted radical cystectomy shows no significant difference in recurrence patterns and oncological outcomes
Tan W, Sridhar A, Ellis G, Lamb B, Goldstraw M, Nathan S, Hines J, Cathcart P, Briggs T, Kelly J. Analysis of open and intracorporeal robotic assisted radical cystectomy shows no significant difference in recurrence patterns and oncological outcomes. Urologic Oncology Seminars And Original Investigations 2016, 34: 257.e1-257.e9. PMID: 26968561, DOI: 10.1016/j.urolonc.2016.02.010.Peer-Reviewed Original ResearchConceptsRecurrence free survivalCancer-specific survivalOpen radical cystectomyORC cohortOverall survivalRadical cystectomySpecific survivalNo significant differenceOncological outcomesSignificant differenceOpen radical cystectomy casesPositive surgical margin rateIntracorporeal robot-assisted radical cystectomyRobotic-assisted radical cystectomyRobot-assisted radical cystectomyEarly oncologic outcomesPreoperative chemotherapy useSurgical margin rateLymph node yieldMedian follow-upKaplan-Meir analysisCox regression analysisIntracorporeal urinary diversionRecurrence patternsPT0 status
2015
Robot‐assisted intracorporeal pyramid neobladder
Tan W, Sridhar A, Goldstraw M, Zacharakis E, Nathan S, Hines J, Cathcart P, Briggs T, Kelly J. Robot‐assisted intracorporeal pyramid neobladder. BJU International 2015, 116: 771-779. PMID: 26033321, DOI: 10.1111/bju.13189.Peer-Reviewed Original ResearchConceptsRobot-assisted radical cystectomyMuscle-invasive bladder cancerUrinary tract infectionPostoperative complicationsFunctional outcomesMedian estimated blood lossNight time continenceBilateral pelvic lymphadenectomyEstimated blood lossMedian hospital stayRecurrence-free survivalUpper tract imagingMedian follow-upLate postoperative complicationsEarly postoperative complicationsPort-site herniaUretero-ileal strictureVitamin B12 deficiencyBlocked stentsNeobladder stonePelvic lymphadenectomyOncological outcomesRadical cystectomyOverall survivalBlood loss